ClinicalTrials.gg
RecruitingNCT05452213CAPTOR-BCUpdated Apr 18, 2023

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

A Phase 4 interventional study of Ribociclib in Breast Cancer, Breast Neoplasms and Breast Neoplasm Female, sponsored by Institut fuer Frauengesundheit. Recruiting at 52 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Institut fuer Frauengesundheit · Phase 4, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies testing ribociclib in Breast Neoplasms — 17 open to participants now, 31 under way, 8 of them phase 3. ribociclib · Breast Neoplasms.

Planned enrollment
8th of 70
1,000 · median 116
Started
2022
with 8 others
Phase 4
5 of 70
2 open now
Primary completion
2024-10
later than 3 of 30 live
Registered
47th of 70
by date

Among the 70 studies testing ribociclib in Breast Neoplasms, this one is the 8th largest by planned enrollment, is one of 9 that started in 2022, is one of 5 in phase 4, reaches primary completion later than 3 of the 30 other live ones, and was the 47th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

17 of the 70 studies testing ribociclib in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About ribociclib

ribociclib: first FDA approval 2017 (KISQALI), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing ribociclib in Breast Neoplasms, or all of them as a file.
02

Study summary

This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with ribociclib and standard of care endocrine treatment according to SmPC.

Read the detailed description

This is a prospective, multicenter, phase IV, one-arm, open-label clinical trial investigating patients treated with ribociclib and standard of care endocrine therapy for hormone receptor positive (HR+) / human epidermal growth factor receptor negative (HER2-) advanced breast cancer in the first therapy line. Patients eligible for this trial will receive on-label ribociclib according to Summary of Product Characteristics (SmPC) and as well as the specified inclusion/exclusion criteria.

The survival rates for progression-free survival (PFS) and overall survival (OS) at month 12 are the co-primary objectives. Quality of life and toxicity are secondary objectives. Additionally, there is a comprehensive biomarker discovery and validation program included into the study.

A total of 1000 patients are planned to be enrolled into this trial in 75 trial sites in Germany.

Biomarkers will be evaluated before, during and after treatment or at progression. A comprehensive biospecimens sampling will be done to enable translational research projects and evaluation of potential biomarkers within circulation tumor desoxyribonucleic acid (ctDNA), circulating tumor ribonucleic acid (ctRNA), formaldehyde-fixed paraffin-embedded tissue (FFPE) tissue, Serum, Plasma and circulating immune cells

03

Conditions studied

  • Breast Cancer
  • Breast Neoplasms
  • Breast Neoplasm Female
  • Breast Cancer Female
  • HER2-negative Breast Cancer
  • Hormone Receptor-positive Breast Cancer
  • Advanced Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Indication for treatment with ribociclib in combination with endocrine therapy in the locally advanced or therapy setting according to SmPC. (Previous treatment with cycline dependent kinase 4/6 (CDK4/6) inhibitors is allowed in the setting)
  2. Written prior to beginning of trial specific procedures
  3. Subject must be female and aged ≥ 18 years on the day of signing informed consent
  4. Locally advanced or metastatic breast cancer not amenable to curative treatment
  5. Patient has -negative breast cancer confirmed by local laboratory defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0 or 1+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required to confirm the HER2-negative status (based on the most recently analyzed tissue sample tested by a local laboratory
  6. confirmed estrogen receptor (ER) positive and/ or progesterone receptor (PgR) positive breast cancer determined by core according to local in-house standard.
  7. (QTcF) interval \< 450 ms
  8. Adequate organ function amenable for treatment with ribociclib as assessed by local laboratory
  9. Women of must have a negative urine or serum pregnancy test within 72 h prior to study entry and be willing to use highly effective method of for course of the trial through 21 days after the last dose of trial treatment.
  10. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent participation in a study with an agent/device or within 14 days of study entry or 5 half-lives of the respective investigational agent/device, whichever is longer
  2. Patients who are not treated for advanced HR+, - breast cancer in the therapy setting.
  3. Patient not eligible for treatment with ribociclib according to SmPC or investigator's discretion
  4. Patients who are pregnant or lactating.
  5. Patients with existing or patients who are at significant risk of developing interval (QTc) prolongation. This includes

    • patients with long QT syndrome
    • uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmia
    • electrolyte abnormalities
  6. Patients with known to the active substance of ribociclib, soya, peanut or any other of the of ribociclib.
  7. Patients with active systemic infections (for example, bacterial infection requiring intravenous antibiotics at time of initiating study treatment, fungal infection, or detectable viral infection requiring systemic therapy) or viral load (such as known positivity or with known active or C, for example, hepatitis B surface antigen positive).
  8. Patients with serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (such as severe renal impairment, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in diarrhea).
  9. Patient who do not agree to collection of biospecimens samples (blood, stool, tissue)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Ribociclib

    Drug: Ribociclib

Interventions

  • All patients will receive ribociclib in combination with standard endocrine therapy according to the current SmPC and local in-house standard. Ribociclib will be administered once daily for 21 consecutive days followed by 7 days off treatment (28-day cycle). The daily dose is 600 mg/day. Ribociclib and standard of care endocrine treatment will be prescribed and administered according to investigator's discretion.

06

What researchers measure

Primary outcomes

  1. 12-month PFS rate

    The rate for progression-free survival at month 12 will be calculated.

    Time frame: 12 months

  2. 12-month OS rate

    The rate for overall survival at month 12 will be calculated.

    Time frame: 12 months

Secondary outcomes

  1. 24-month PFS rate

    The rate for progression-free survival at month 24 will be calculated.

    Time frame: 24 months

  2. 24-month OS rate

    The rate for overall survival at month 24 will be calculated.

    Time frame: 24 months

  3. 36-month PFS rate

    The rate for progression-free survival at month 36 will be calculated.

    Time frame: 36 months

  4. 36-month OS rate

    The rate for overall survival at month 36 will be calculated.

    Time frame: 36 months

  5. Median progression-free survival

    Median progression-free survival will be estimated if achieved at the end of study

    Time frame: From date of enrollment until first documented progression or date of death from any cause or regular end of study (up to 24 months) whichever is first.

  6. Median overall survival

    Median overall survival will be estimated if achieved at the end of study

    Time frame: From date of enrollment until date of death from any cause or regular end of study (up to 24 months) whichever is first.

  7. Health related quality of life (FACT-G)

    Health related quality of life as assessed by FACT-G questionnaire (Functional Assessment of Cancer Therapy - General) Min 0, Max 108, The higher the score, the better the QoL.

    Time frame: Collected before start of trial treatment, at 3 months and every 6 months afterwards until end of study up to 24 months

  8. Health related quality of life (FACT-B)

    Health related quality of life as assessed by FACT-B questionnaire (Functional Assessment of Cancer Therapy - Breast Cancer) Min 0, Max 148, The higher the score, the better the QoL.

    Time frame: Collected before start of trial treatment, at 3 months and every 6 months afterwards until end of study up to 24 months

  9. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    The safety endpoints for the study will include rate of adverse events (AE), serious adverse events (SAEs) and fatal SAEs, causality and outcome of AE/SAEs, rate of treatment discontinuations and reasons, Changes in vital signs, laboratory values etc. Grading of AE/SAEs will be based on NCI CTCAE v5.0.

    Time frame: All adverse events will be recorded from signing informed consent through 30 days following cessation of treatment or until the last study visit

Other outcomes

  1. Correlation of genome wide genetic biomarkers with progression-free survival

    Genome wide genetic biomarkers will be assessed by whole genome sequencing and/ or panel sequencing from blood samples.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  2. Correlation of genome wide genetic biomarkers with overall survival

    Genome wide genetic biomarkers will be assessed by whole genome sequencing and/ or panel sequencing from blood samples.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  3. Correlation of genome wide genetic biomarkers with quality of life

    Genome wide genetic biomarkers will be assessed by whole genome sequencing and/ or panel sequencing from blood samples.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  4. Correlation of genome wide genetic biomarkers with ribociclib side effects

    Genome wide genetic biomarkers will be assessed by whole genome sequencing and/ or panel sequencing from blood samples.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  5. Correlation of genome wide gene expression biomarkers with progression-free survival

    Genome wide genetic biomarkers will be assessed by whole genome sequencing and/ or panel sequencing from blood samples.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  6. Correlation of genome wide gene expression biomarkers with overall survival

    Genome wide genetic biomarkers will be assessed by whole genome sequencing and/ or panel sequencing from blood samples.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  7. Correlation of genome wide gene expression biomarkers with quality of life

    Genome wide genetic biomarkers will be assessed by whole genome sequencing and/ or panel sequencing from blood samples.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  8. Correlation of genome wide gene expression biomarkers with ribociclib side effects

    Genome wide genetic biomarkers will be assessed by whole genome sequencing and/ or panel sequencing from blood samples.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  9. Correlation of genome wide tumor mutational patterns assessed from formalin-fixed paraffin embedded tumor material with progression-free survival

    Tumor DNA will be either isolated from FFPE tissue (primary tumor or metastasis) or from Plasma samples (STRECK cfDNA Tube). DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline and at the time of tumor progression

  10. Correlation of genome wide tumor mutational patterns assessed from formalin-fixed paraffin embedded tumor material with overall survival

    Tumor DNA will be either isolated from FFPE tissue (primary tumor or metastasis) or from Plasma samples (STRECK cfDNA Tube). DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline and at the time of tumor progression

  11. Correlation of genome wide tumor mutational patterns assessed from formalin-fixed paraffin embedded tumor material with quality of life

    Tumor DNA will be either isolated from FFPE tissue (primary tumor or metastasis) or from Plasma samples (STRECK cfDNA Tube). DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline and at the time of tumor progression

  12. Correlation of genome wide tumor mutational patterns assessed from formalin-fixed paraffin embedded tumor material with ribociclib side effects

    Tumor DNA will be either isolated from FFPE tissue (primary tumor or metastasis) or from Plasma samples (STRECK cfDNA Tube). DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline and at the time of tumor progression

  13. Correlation of genome wide tumor mutational patterns assessed from ctDNA biomarkers with progression-free survival

    Germline DNA will be isolated from one EDTA blood samples obtained within the study. DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  14. Correlation of genome wide tumor mutational patterns assessed from ctDNA biomarkers with overall survival

    Germline DNA will be isolated from one EDTA blood samples obtained within the study. DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  15. Correlation of genome wide tumor mutational patterns assessed from ctDNA biomarkers with quality of life

    Germline DNA will be isolated from one EDTA blood samples obtained within the study. DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  16. Correlation of genome wide tumor mutational patterns assessed from ctDNA biomarkers with ribociclib side effects

    Germline DNA will be isolated from one EDTA blood samples obtained within the study. DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  17. Correlation of changes in the genome wide tumor mutational patterns assessed from ctDNA biomarkers with progression-free survival

    Germline DNA will be isolated from one EDTA blood samples obtained within the study. DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  18. Correlation of changes in the genome wide tumor mutational patterns assessed from ctDNA biomarkers with overall survival

    Germline DNA will be isolated from one EDTA blood samples obtained within the study. DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  19. Correlation of changes in the genome wide tumor mutational patterns assessed from ctDNA biomarkers with quality of life

    Germline DNA will be isolated from one EDTA blood samples obtained within the study. DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

  20. Correlation of changes in the genome wide tumor mutational patterns assessed from ctDNA biomarkers with ribociclib side effects

    Germline DNA will be isolated from one EDTA blood samples obtained within the study. DNA will be analyzed by whole genome sequencing and/or panel sequencing.

    Time frame: Measured from biomaterial collected at baseline, 2 weeks, 3 months, 6 months, 12 months, 18 months or at the end of treatment in case treatment is stopped irregularly.

07

Study locations

28 of 52 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Oct 2024, 24 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 24 months is below that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2022
First posted
Jul 11, 2022
StartActual
Oct 12, 2022
Primary completionEst.
Oct 2024
CompletionEst.
Oct 2026
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05452213
Lead sponsor
Institut fuer Frauengesundheit
Collaborators
AGO Breast Study Group e.V., Novartis Pharmaceuticals
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Oct 12, 2022
Primary completion
Oct 2024 (estimated)
Completion
Oct 2026 (estimated)
Last update
Apr 18, 2023

Study contacts

CAPTOR Study Manager
Contact
captor@ifg-erlangen.de
09131 9278638
Peter A. Fasching, MD, Prof.
study chair · Department of Gynecology and Obstetrics, Erlangen University Hospital
Tanja Fehm, MD, Prof.
study chair · Department of Gynecology/Obstetrics |University Hospital Düsseldorf, Germany
Andreas Schneeweiss, MD, Prof.
study chair · National Center for Tumor Diseases (NCT) | Heidelberg University Hospital and German Cancer Research Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribociclib

Start the discussion